What did @gina.nacnac actually say?
The creator listed three goals she says women over 40 typically have: weight management, growth, and better energy and focus. For weight, she pointed to tirzepatide and semaglutide ("the one that rhymes with meta"). For growth, she recommended growth hormone-releasing peptides, specifically CJC-1295 and ipamorelin. For energy, she brought up NAD+, then quickly acknowledged it "is not really a peptide." For focus, she recommended Semax as a nasal spray, calling that format a plus because "you're not pinning a million things."
She also directed viewers to comment for a "trusted source," which in this context almost certainly means a peptide vendor or compounding pharmacy referral. That detail matters for evaluating her overall credibility and intent here.
Does the science back this up?
It depends heavily on which compound you're looking at. The GLP-1 and GIP receptor agonist claims have the strongest evidence base. The growth peptide stack is plausible but overstated. The Semax claim for focus is real but thin. NAD+ is largely unproven at the supplement level.
Tirzepatide has robust Phase 3 trial data. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed an average 20.9% body weight reduction in adults with obesity over 72 weeks. Semaglutide's STEP 1 trial (Wilding et al., 2021, NEJM) showed 14.9% average weight loss. These are not peptide therapy in the traditional optimization sense, they are FDA-approved medications with serious side effect profiles and prescribing requirements.
CJC-1295 and ipamorelin together stimulate growth hormone release. Small studies show modest IGF-1 increases (Teichman et al., 2006, Journal of Clinical Endocrinology and Metabolism), but long-term safety data in healthy aging women is genuinely sparse. Semax has real neurotrophin-related mechanisms studied primarily in Russian literature, with some evidence for BDNF upregulation in animal models, but robust human RCTs are essentially absent in Western literature.
What did they get wrong (or right)?
She got credit for the NAD+ admission. Saying it "is not really a peptide" is accurate and more honest than most wellness influencers get. That's worth noting. She also correctly identified tirzepatide and semaglutide as weight-relevant compounds, even if she softened the language around them.
What she got wrong, or at minimum glossed over, is significant. Lumping FDA-approved medications like semaglutide and tirzepatide into a casual "peps" recommendation ignores that these are controlled substances requiring medical supervision, labs, and ongoing monitoring. Presenting them alongside unregulated research compounds creates a false equivalence about safety profiles and regulatory status.
The growth hormone stack recommendation is also looser than it should be. CJC-1295 and ipamorelin are not FDA-approved for anti-aging or general wellness use. The FDA has specifically cracked down on compounded versions of these peptides. Recommending "one of the orlins" without any safety context for women who may have thyroid issues, active tumors, or hormonal imbalances is genuinely irresponsible.
The Semax nasal spray framing as convenient because "you're not pinning a million things" is cute but misleading. Route of administration convenience is not a proxy for safety or efficacy validation.
What should you actually know?
These compounds are not interchangeable, and they do not carry equal levels of evidence or regulatory oversight. That matters before anyone considers any of them.
- Tirzepatide and semaglutide are FDA-approved medications. They require a prescription, baseline labs, and medical follow-up. Side effects include nausea, pancreatitis risk, thyroid C-cell tumor signals in animal studies, and muscle mass loss without resistance training.
- CJC-1295 and ipamorelin are research compounds. The FDA placed many compounded peptides on a category of increased oversight in 2023-2024. Their legal status for compounding is actively shifting.
- Semax has a real pharmacological mechanism but no FDA approval and limited English-language human trial data. Using it based on influencer recommendations is a significant leap.
- NAD+ precursors like NMN and NR have more clinical data than straight NAD+ infusions or supplements, and even those results are mixed. Rajman et al. (2018, Cell Metabolism) outlined the theoretical basis, but translation to clear clinical outcomes in humans remains inconsistent.
- Anyone receiving a vendor referral from a comment-section DM should verify that source is a licensed, regulated pharmacy, not a grey-market peptide supplier.